

# 拥有 40 年历史的 Rx- pharma 制造业务





## 40 Rx-pharma

这家待售公司是一家位于印度班加罗尔的医疗保健公司。

该业务涉及为全球人民制造和供应药品和营养补充剂（符合 WHO-GMP 和 ISO 认证规定的质量标准）。

该业务设备齐全，符合 ISO 9001 和 WHO GMP

认证单位，可满足来自中美洲、尼日利亚、孟加拉国、柬埔寨、斯里兰卡、马来西亚、多米尼加共和国等国家的订单。该单位拥有超过 50000 平方英尺的建筑面积，专门用于片剂、胶囊剂和口服液的生产。

公司生产仿制药、保健品和草药产品。

3

收入在过去 3 年稳步增长，但 EBITDA 有所下降。EBITDA 的减少是由于 5

年前开始的在线品牌广告支出增加。这个 D2C

补充剂品牌所获得的任何利润都被重新投入到该品牌的营销中，这导致了整个公司的 EBITDA 减少。

438 个仿制药生产许可证。其中，公司目前持有 148 项 CoPP 批准，允许我们在多个 ROW 国家注册我们的产品出口。

具有成本优势的小规模制造设施的高生产能力。

位于班加罗尔市内的制造单位允许获得熟练和非熟练劳动力。

**TARGET PRICE**

\$12,000,000

**GROSS REVENUE**

\$1,900,000

**EBITDA**

\$0

**BUSINESS TYPE**

制造业

**ESTABLISHED**

1982

**SUPPORT & TRAINING**

1年

**REASON FOR SELLING**

退休

**COUNTRY**

印度

**BUSINESS ID**

L#20210016

*The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction.*

*The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.*

*By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.*

*This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.*

*The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.*

*All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.*

[www.mergerscorp.com](http://www.mergerscorp.com)



[WWW.MERGERSCORP.COM](http://WWW.MERGERSCORP.COM)